newsfilter
← Latest News
PR Newswire·

TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

  • Faruqi & Faruqi, LLP is investigating potential securities claims against Tvardi Therapeutics, Inc. (NASDAQ: TVRD).
  • Tvardi's parent company, Moonlake Immunotherapeutics, saw shares fall over 80% on October 13, 2025, following disappointing preliminary data from the Phase 2 REVERT clinical trial for TTI-101.
  • The study aimed to assess safety, pharmacokinetics, & exploratory outcomes regarding lung function in patients with idiopathic pulmonary fibrosis.
  • Tvardi concluded the study did not meet its goals after reviewing preliminary safety data & efficacy results, including Forced Vital Capacity (FVC) changes.
  • Investors who suffered losses may contact partner James (Josh) Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss legal options.
  • The firm has offices in New York, Pennsylvania, California, & Georgia, having recovered hundreds of millions of dollars for investors since 1995.